Hybrigenics’ inhibitor of Ubiquitin-Specific Protease 7 (USP7) shows activity in preclinical models of Chronic Lymphocytic Leukemia (CLL)

18 May 2017 18:00 CEST

Company Name

ATON

ISIN

FR0004153930

Market

Euronext Growth

Symbol

ALTAO

Connect_pr_cll_usp7_final_en.pdf

Source

HYBRIGENICS

Provider

Home
Markets
- Amsterdam
  - Cash Products
    - Stocks
      - AEX index Stocks
      - AEX ESG Stocks
    - Indices
    - Funds
    - Bonds
    - ETFs
    - Structured products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
- Brussels
  - Cash products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
  - Expert Market
- Dublin
- Lisbon
  - Cash Products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
- Milan
  - Cash Products
  - Derivative products
  - IPOs
- Oslo
  - Cash Products
  - Derivatives
    - Derivative products
    - Quote Vendor Codes
  - Company regulated news
    - Latest
    - Archive
  - Financial calendars
  - Primary insiders
- Paris
  - Cash Products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
Equities
- All Markets directories
- Company regulated news
  - Latest
  - Archive
- IPOs
  - All IPOs
- Listing sponsors
- Euronext Tech Leaders
- Family business
Indices
ETFs
- Directory
- ESG ETFs
Funds
Fixed Income
- ESG Bonds
- 1.5° Bonds
- All Markets directories
  - All Markets
  - Amsterdam
  - Brussels
  - Dublin
  - Lisbon
  - Oslo
  - Milan
  - Paris
Structured Products
Equity Derivatives
Commodities
Knowledge Centre
Resources